Production of a short recombinant C4V3 HIV-1 immunogen that induces strong anti-HIV responses by systemic and mucosal routes without the need of adjuvants

Viral Immunology

Volumn 19, Issue 2, 2006, Pages 237-249

  Varona Santos, Javier T ^a   Vazquez Padrón, Robert I ^b   Moreno Fierros, Leticia ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; EPITOPE; HISTIDINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; POLYPEPTIDE; PROTEIN RC4V3; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; COST; DRUG DESIGN; DRUG MECHANISM; ESCHERICHIA COLI; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; LARGE SCALE PRODUCTION; MEDICAL RESEARCH; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PROCESS TECHNOLOGY; PROTEIN FOLDING; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745875334     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.237     Document Type: Article

References (45)

1. Agrawal, L., W. Haq, C. Hanson, D. Rao. 2003. Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-1 env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity. J. Immune Based Ther Vaccines 1: 1-22.
2. Ahlers, J., T. Takeshita, C. Pendleton, J. Berzofsky. 1997. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence Proc. Natl. Acad. Sci. USA 94: 10856-10861.
3. Barouch, D., J. Kunstman, M. Kuroda, J. Schmitz, S. Santra, F. Peyerl, G. Krivulka, K. Beaudry, M. Lifton, D. Gorgone, D. Montefiori, M. Lewis, S. Wolinsky, N. Letvin. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415: 335-339.
4. Belyakov, I., M. Derby, J. Ahlers, B. Kelsall, P. Earl, B. Moss, W. Strober, J. Berzofsky. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA 95: 1709-1714.
5. Berstad, A. K., J. Holst, B. Mongster, I. L. Haugen, B. Haneberg. 1997. A nasal whole-cell Pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin. Vaccine 15: 1473-1478
6. Berzofsky J.A., J.D. Ahlers, J. Janik, J. Morris, S-K Oh, M. Terabe, I. M. Belyakov. 2004. Progress on new vaccine strategies against chronic viral infections. The J. of Clin. Investig. 114: 450-462
7. Bouvet, J-P., N. Decroix, P. Pamonsinlapatham. 2002. Stimulation of local antibody production: parenteral or mucosal vaccination? Trends in Immunol. 23: 209-213.
8. Bourinbaiar, A., O. Metadilogkul, V. Jirathitikal. 2003. Mucosal AIDS Vaccines. Viral Immunol. 16: 427-445.
9. Bradney, C., G. Sempowski, H-X. Liao, B. Haynes, H. Staats. 2002. Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization. J. Virol. 76: 517-524.
10. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5: 233-236.
11. Chen H. 2000. Recent advances in mucosal vaccine development. J. of Controlled Release 67: 117-128.
12. Decroix, N., H. Hocini, C. Quan, B. Bellon, M. Kazatchkine, J-P. Bouvet. 2001. Induction in mucosa of IgG and IgA antibodies against parenterally administered soluble immunogens. Scand. J. Immunol. 53: 401-409.
13. Decroix, N., P. Pamonsinlapatham, C. Quan, J-P. Bouvet. 2002. Mucosal immunity induced by intramuscular administration of free peptides in-line with PADRE: IgA antibodies to the ELDKWA epitope of HIV gp41.Scand. J. Immunl. 56: 59-65.
14. Decroix, N., P. Pamonsinlapatham, C. Quan, J-P. Bouvet. 2003. Impairment by mucosal adjuvants and cross-reactivity with variant peptides of the mucosal immunity induced by injection of the fusion peptide PADRE-ELDKWA. Am. Soc. Microbiol. 10: 1103-1108.
15. De Vito C., B. Zuber, U. Shröder, R. Benthin, K. Okuda, K. Broliden, B. Wahren, J. Hinkula. 2004. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in-long term HIV-1 neutralizing humoral mucoal and systemic immunity. J. Immunol. 175: 7078-7089.
16. Fernández, I., H. Gelding, B. Benaissa-Trouw, N. de Vos, M. Harmsen, H. Nottet, B. Golding, W. Puijk, R. Meloen, H. Snippe, C. Kraaijeveld. 1998. Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimaeric peptide consisting of a T-helper cell epitope of Semliki Forest virus and a B-cell epitope of HIV. Vaccine 16: 1936-1940.
17. Gaschen B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. Haynes, B. H. Hahn, T. Bhattacharya, B. Korber. 20002. Diversity consideration in HIV-1 vaccine selection. Science 296: 2354-2360.
18. Golding, B., N. Eller, L. Levy, P. 2002. Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus. Vaccine 20: 1445-1450.
19. Grundstrom, T., W. M. Zenke, M. Wintzerith, H. W. D. Matthes, A. Staub, A. & P. Chambon. 1985. Oligonucleotide-directed mutagenesis by microscale 'shot-gun' gene synthesis. Nucl. Acids Res. 13: 3305-3316.
20. Hamajima, K., H. Bukawa, J. Fukushima, S. Kawamoto, T. Kaneko, Sekigawa K., S. Tanaka, M. Tsukuda, K. Okuda. 1995. A macromolecular multicomponent peptide vaccine prepared using the glutaraldehide conjugation method with strong immunogenicity for HIV-1. Clin. Immunol. and Immunopathol. 77: 374-379.
21. Hart MK, K.J. Weinhold, R.M. Scearce, E.M. Washburn, C.A. Clark, T.J. Palker, B.F. Haynes. 1991. Priming of antihuman immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc Natl Acad Sci USA. 88(21): 9448-9452.
22. MN neutralizing antibodies in primates using a prime-boost regimen of hibrid synthetic gp 120 envelope peptides. J. Immunol. 151: 1646-1653.
23. Haynes B.F., Benjiang Ma, D.C. Montefiori, Wrin T., Petropoulos C.J., Sutherland L.L., Scearce R.M., Denton C., Xia S-M, Kjorber B.T., Liao H-X. 2005. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology (article in press)
24. Hewer, R.; D. Meyer. 2002. Producing a highly immunogenic synthetic vaccine construct active against HIV-1 subtype C. Vaccine 20: 2680-2683.
25. Hjemel, L. M., Andreas Chrambach. 2005. Electrophoresis and electrofocusing in detergent containing media: A discussion of basic concepts. Electrophoresis 2: 1-11
26. Holmgren, J., C. Czerkinsky, K. Eriksson, A. Mharandi. 2003. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21: S2/89-S2/95
27. Hordnes, K., T. Tynning, T. A. Brown, B. Haneberg, R. Jonsson. 1997. Nasal immunization with group streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 15: 1244-1251
28. Kane, J. 1995. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr. Opinion in Biotechnol. 6: 494-500
29. Kato, H., H. Bukawa, E. Hagirawa, K. Xin, K. Hamajima, S. Kawamoto, M. Sigiyama, E. Noda, M. Nishizaki, K. Okuda. 2000. Rectal and vaginal immunization with a macromolecular muticomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses. Vaccine 18: 1151-1160
30. Kim T-G., N. Befus, Langridge W.H.R. 2004. Co-immunization with an HIV-1 Tat transduction peptide-rotavirus enterotoxin fusion protein stimulates a Th1 mucosal immune response in mice. Vaccine 22: 431-438
31. Lawoko, A., B. Johansson, S. Hjalmarsson, B. Christensson, B. Ljungberg, L. Al-Khalili, M. Sjölund, R. Pipkorn, E. Fenyö, J. Blomberg. 1999. Comparative Studies on Neutralization of primary HIV-1 Isolates by Human Sera and Rabbit Anti-V3 Peptide. J. Med. Virol 59: 169-179.
32. Letvin, N., S. Robinson, D. Rohne, M. Axthelm, J. Fanton, M. Bilska, T. Palker, H-X. Liao, B. Haynes, D. Montefiori. 2001. Vaccine-elicited V3 Loop-Specific Antibodies in Rhesus Monkeys and Control of a Simian-Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate Envelope. J. Virol. 75: 4165-4175.
33. Liao, H-X, Etemad-Moghadam B., Montefiori D.C., Sun Y., Sodrosky J., Scerace R.M., Doms R.W., Thomasch J.R., Robinson S., Letvin N.L., Haynes B.F. 2000. Induction of antibodies in guinea pigs and rhesus monkeys against the HIV-1 envelope: neutralization of non-pathogenic and pathogenic primary isolate SHIV strains. J. Virol. 74: 254-263.
34. Lu, Y., Y. Xiao, J. Ding, M. Dierich, Y-H. Chen. 2000. Multiepitope Vaccines Intensively Increased Levels of Antibodies Recognizing Three Neutralizing Epitopes on Human Immunodeficiency Virus-1 Envelope Protein. Scand. J. Immunol. 51: 497-501.
35. Moreno-Fierros, L., A. Reséndiz-Albor, R. Lopez-Revilla. 1999. Different antiamoebic antibody isotype patterns in the large and small intestine after local and systemic immunization of mice with glutaraldehyde fixed Entamoeba histolytica trophozoites. Life Sci. 64: 1079-1089.
36. O'Hagan, D., E. Lavelle. 2002. Novel adjuvants and delivery systems for HIV vaccines. AIDS 16: 5115-5124.
37. Rojas-Hernández, S., M.A. Rodríguez-Monroy, R. Lopez-Revilla, A.A. Reséndiz-Albor, L. Moreno-Fierros. 2004. Intranasal co-administration of Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis. Infect. Immun. 72: 4368-4375.
38. Saavedra, R., E. Segura, R Leyva, L.A. Esparza, L.M. Lopez-Marín. 2001. Mycobacterial di-O-acyl-trehalose inhibits mitogen- and antigen-induced proliferation of murine T cells in vitro. Clin. Diagn. Lab. Immunol. 8: 1081-1088.
39. Staats, H., W. Nichols, T. Palker. 1996. Mucosal Immunity to HIV-1. Systemic and vaginal antibody responses after intranasal Immunization with the HIV-1 C4/V3 Peptide T1SP10 MN(A). J. Immunol. 157: 462-472.
40. Staats, H., S. Montgomery, T. Palker. 1997. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Research and Human Retroviruses. 13: 945-952
41. Takahashi H, J. Cohen, A. Hosmalin, KB Cease, R Houghten, JL Cornette, C DeLisi, B. Moss, RN. Germain, JA. Berzofsky. 1988. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gploO recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA. 85(9): 3105-3109.
42. Takahashi H, R. Houghten, S.D. Putney, D.H. Margulies, B. Moss, R.N. Germain, J.A. Berzofsky JA. 1989. Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein. J Exp Med. 170(6): 2023-2035.
43. Wingfield, P., J.E. Dunn, B. M. Ploegh, H. L. Speicher, D. W. Coligan. 1995. Overview of the purification of recombinant proteins produced in Escherichia coli: 6.1.1-6.1.22. eds. John Wiley and Sons. Current Protocols in Protein Science. Vol. 1, John Wiley and Sons Inc., New York
44. Yao, Q., V. Vuong, M. Li, R. Compans. 2002. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine 20: 2537-2545.
45. Zolla-Pazner S. 2004. Identifying epitopes of HIV-1 that induce protective antibodies. Nature Reviews 4: 199-210.